publication date: Aug. 3, 2018

NCI Trials NCI Trials for August

NCI approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase II – 10166

A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Liu, Stephen V.

(202) 444-8535


Phase II – A031701

A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Alliance for Clinical Trials in Oncology

Iyer, Gopakumar V.

(646) 422-4362


Phase III – A021602

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)

Alliance for Clinical Trials in Oncology

Chan, Jennifer Ang

(617) 632-6315


Phase III – A211601

Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502

Alliance for Clinical Trials in Oncology

Wood, Marie Elizabeth

(802) 656-5487

Continue reading NCI Trials for August 2018

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.